Penumbra Reports Strong 2025 Growth Amid Boston Scientific Acquisition
Event summary
- Penumbra reported $385.4M in Q4 2025 revenue, up 22.1% YoY, with full-year 2025 revenue reaching $1.4B, a 17.5% increase.
- U.S. thrombectomy revenue grew 19.3% YoY to $771.5M in 2025, while embolization and access products saw a 25.4% increase in U.S. sales.
- Net income for 2025 was $177.7M, with an operating margin of 13.5%, up from $9.3M in 2024.
- The company will not provide 2026 financial guidance due to the proposed acquisition by Boston Scientific.
The big picture
Penumbra's strong financial performance in 2025 underscores its leadership in thrombectomy and embolization technologies. The proposed acquisition by Boston Scientific signals a strategic shift towards consolidating expertise in minimally invasive medical solutions, potentially reshaping the competitive landscape in vascular interventions.
What we're watching
- Integration Challenges
- How Penumbra's operational integration with Boston Scientific will impact product development and market positioning.
- Regulatory Approvals
- The pace at which the acquisition receives necessary regulatory approvals and potential delays.
- Market Competition
- Whether the combined entity can sustain growth amid increasing competition in the medical device sector.
Related topics